Cowen Upgrades Exelixis (EXEL) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Cowen Upgrades Exelixis (EXEL) to Outperform
November 4, 2014 4:54 PM EST
Exelixis (NASDAQ: EXEL) reported Q3 EPS of ($0.32), $0.05 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $6.3 million versus the consensus estimate of $6.77 million.
For earnings history and earnings-related data on Exelixis (EXEL) click here.
...
More
November 4, 2014 4:21 PM EST
Exelixis, Inc. (NASDAQ: EXEL) today announced positive top-line results from a randomized phase 2 trial of cabozantinib and erlotinib alone or in combination as second- or third-line therapy in patients with stage IV EGFR wild-type non-small cell lung cancer (NSCLC). This trial (Study E1512) is sponsored by the U.S. National Cancer Institute (NCI) through a Cooperative Research and Development Agreement between the Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and Diagnosis, NCI and Exelixis. Study E1512 was designed and is being conducted by the ECOG-ACRIN Cancer Research Group as part of Exelixis... More
